Piramal Pharma Q2 FY27: PAT ₹-69 & Rev ₹2,270 Cr

1 Financial Results 🔴 High Importance ✨ Positive 📄 PDF

Investor Takeaways

Revenue grew 17% YoY to ₹2,270 crores in Q1 FY27

EBITDA surged 72% to ₹285 crores with margin expanding to 12.5%

PAT after exceptional items improved 15% YoY to ₹(69) crores

Overall Tone: Positive

Key Financial Highlights

Metric	Value	YoY Change
Revenue	₹2,270 Cr	+17%
Net Profit	₹(69) Cr	+15%
EBITDA	₹285 Cr	+72%
OPM	12.5%	—
EPS	Not available	—

What Changed

The company delivered strong operational momentum in Q1 FY27, with consolidated revenue increasing 17% YoY to ₹2,270 crores, driven by growth across CDMO, CHG, and PCH segments. EBITDA surged 72% to ₹285 crores, accompanied by margin expansion to 12.5% from 8.5%, reflecting improved operating leverage and execution efficiency. Net profit after exceptional items turned positive with a 15% YoY improvement to ₹(69) crores, indicating better cost control and profitability. The company highlighted robust order inflows, FDA approval at its Sellersville facility, and plans to commence Kenalog supplies in Q2FY27. However, no forward guidance was provided in the filing. Compared to peers, Piramal Pharma’s P/E ratio of 582.9 is significantly higher than Sun Pharmaceutical (41.28), Divi's Laboratories (72.41), and Torrent Pharmaceuticals (80.06), suggesting premium valuation expectations. The company’s ROE and ROCE were not disclosed in the provided data.

Peer Comparison

Company	P/E	ROE	ROCE	Market Cap (₹ Cr)
Piramal Pharma	582.9	Not available	Not available	23,244.56
Sun Pharmaceutical	41.28	15.11%	20.34%	4,50,643.09
Divi's Laboratories	72.41	16.56%	22.09%	1,79,470.03
Torrent Pharmaceuticals	80.06	N/A	N/A	1,49,108.91

Piramal Pharma’s valuation appears stretched relative to peers on P/E basis, though its margin expansion and profitability trajectory may justify some premium.

Risks & Concerns

No specific risks identified in this filing

PAT remains negative despite improvement, indicating ongoing restructuring or investment phase

High P/E ratio may pressure investor sentiment if profitability does not accelerate

Quarterly Trend

Quarter	Revenue (₹ Cr)	Net Profit (₹ Cr)	OPM%
Q3FY25	2,204.22	3.68	15.32
Q2FY25	2,241.75	22.59	15.24
Q1FY25	1,951.14	-88.64	10.48
Q4FY24	2,552.36	101.27	20.76

The current quarter’s revenue (₹2,270 Cr) and PAT (₹(69) Cr) align with the sequential improvement trend, though profitability remains volatile. OPM has fluctuated significantly over the past four quarters, peaking at 20.76% in Q4FY24 before moderating to 12.5% in Q1FY27.

2 Financial Results 🔴 High Importance ✨ Positive 📄 PDF

📢 Key Event
Piramal Pharma announces Q1FY27 results with 17% revenue growth and 72% EBITDA surge

🔄 What Changed
Revenue grew 17% YoY to ₹2,270 crores; EBITDA rose 72% to ₹285 crores; EBITDA margin expanded to 12.5%; PAT after exceptional items declined 15% YoY to (69) crores

🔮 What's Next
Expect sustained revenue growth and EBITDA expansion through FY27

💡 Investor Takeaway
The company delivered strong top-line growth and margin expansion across all segments, signaling robust operational momentum for the new fiscal year.

Piramal Pharma reported consolidated revenue of ₹2,270 crores for Q1FY27, up 17% YoY, driven by growth across CDMO, CHG, and PCH segments. EBITDA rose 72% to ₹285 crores, with margin expanding to 12.5% from 8.5%, reflecting improved operating leverage. PAT after exceptional items was (69) crores, a 15% decline YoY, primarily due to lower exceptional gains. The company highlighted strong order inflows in CDMO, sustained leadership in inhalation anesthesia, and profitable growth in Consumer Healthcare. It expects sustained revenue growth and EBITDA expansion through FY27, supported by strategic investments and capacity additions.

📊 Stock Analysis — PPLPHARMA ✨ Ask AI About This

About Piramal Pharma Limited (PPLPHARMA)

Healthcare · Pharmaceuticals & Biotechnology · Listed on NSE

Market Cap: ₹23,244.56 Cr P/E: 582.9

View full PPLPHARMA stock details →

📡 Get AI alerts when PPLPHARMA files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track PPLPHARMA — Free

💡 Ask AI about this filing

"How does the 17% revenue growth compare to peers in the CDMO and generics space?" "What is the expected impact of Kenalog supply starting in Q2FY27 on CHG revenue?" "What is the company's target EBITDA margin expansion for FY27?"

Ask AI Free →

📊 More PPLPHARMA filings

See all PPLPHARMA filings →

🔥 Also filed on 29 July 2026

SUZLON Suzlon Energy Limited Corporate Action DABUR Dabur India Limited Financial Results SYRMA Syrma SGS Technology Limited Financial Results KROSS Kross Limited Financial Results ASIANPAINT Asian Paints Limited Financial Results CREDITACC CREDITACCESS GRAMEEN LIMITED Financial Results

View all today's announcements →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when PPLPHARMA files new disclosures

Track PPLPHARMA filings, board meetings, and corporate actions. Free email alerts at 5 PM.